Trial Profile
Phase II of Immunotherapy Plus Local Tumor Ablation (RFA or Stereotactic Radiotherapy) in Patients With Colorectal Cancer Liver Metastases
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Colorectal cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms ILOC
- 23 Feb 2023 New trial record
- 21 Jan 2023 Status has been changed to discontinued, Results presented at the 2023 Gastrointestinal Cancers Symposium
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium